Prognostic significance of soluble Fas in the serum of patients with bladder cancer

Journal of Urology

Volumn 160, Issue 2, 1998, Pages 571-576

  Mizutanil, Youichi ^a   Yoshida, Osamu ^b   Bonavida, Benjamin ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Anti autologous tumor cytotoxicity; Bladder cancer; Fas; Prognosis; sFas

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032323358     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62960-4     Document Type: Article

References (30)

1. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. and Golstein, P.: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265: 528, 1994.
2. Arase, H., Arase, N. and Saito, T.: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med., 181: 12358, 1995.
3. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponstingl, H. and Krammer, P. H.: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J. Biol. Chem., 267: 10709, 1992.
4. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S. I., Sameshima, M., Hase, A., Seto, Y. and Nagata, S.: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233, 1991.
5. Watanabe-Fukunaga, R., Brannan, C. I., Itoh, N., Yonehara, S., Copeland, N. G., Jenkins, N. A. and Nagata, S.: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol., 148: 1274, 1992.
6. Nagata, S.: Fas and Fas ligand: a death factor and its receptor. Adv. Immunol., 57: 129, 1994.
7. Cheng, J., Zhou, T., Lie, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J. and Mountz, J. D.: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 263: 1759, 1994.
8. Cascino, I., Fiucci, G., Papoff, G. and Ruberti, G.: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154: 2706, 1995.
9. Natoli, G., Ianni, A., Costanzo, A., De Petrillo, G., Ilari, I., Chirillo, P., Balsano, C. and Levrero, M.: Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene, 11: 1157, 1995.
10. Knipping, E., Debatin-K. M., Stricker, K., Heilig, B., Eder, A. and Krammer, P. H.: Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood, 85: 1562, 1995.
11. Midis, G. P., Shen, Y. and Owen-Schaub, L. B.: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res., 56: 3870, 1996.
12. Sato, T., Irie, S., Kitada, S. and Reed, J. C.: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science, 268: 411, 1995.
13. L. Immunology, 3: 87, 1995.
14. Zornig, M., Grzeschiezek, A., Kowalski, M. H., Hartmann, K. U. and Moroy, T.: Loss of Fas/APO-1 receptor accelerates lymphomagenesis in Eμ L-MYC transgenic mice but not in animals infected with MoMuf. V. Oncogene, 10: 2397, 1995.
15. Mizutani, Y., Okada, Y., Terachi, T. and Yoshida, O.: Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with urinary bladder cancer. J. Urol., 155: 888, 1996.
16. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida, O.: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res., 55: 590, 1995.
17. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients urinary bladder cancer. Cancer, 69: 537, 1992.
18. Mizutani, Y., Nio, Y. and Yoshida, O.: The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer, 69: 2999, 1992.
19. Mizutani, Y., Okada, Y., Yoshida, O., Fukumoto, M. and Bonavida, B.: Adriamycin sensitizes human bladder cancer cells to Fas-mediated cytotoxicity. Cancer, 79: 1180, 1997.
20. Mizutani, Y., Okada, Y., Yoshida, O. and Bonavida, B.: Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer. Cancer Biother. Radiopharm., 11: 385, 1996.
21. Hasunuma, T., Kayagaki, N., Asahara, H., Motokawa, S., Kobata, T., Yagita, H., Aono, H., Sumida, T., Okumura, K. and Nishioka, K.: Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheumatism, 40: 80, 1997.
22. Munker, R., Midis, G., Owen-Schaub, L. and Andreff, M.: Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia, 10: 1531, 1996.
23. Liu, C. C., Young, L. H. Y. and Young, J. D. E.: Lymphocyte-mediated cytolysis and disease. N. Engl. J. Med., 335: 1651, 1996.
24. Lowin, B., Hahne, M., Mattmann, C. and Tschopp, J.: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature, 370: 650, 1994.
25. Moller, P., Henne, C., Leithauser, F., Eichelmann, A., Schmidt, A., Bruderlein, S., Dhein, J. and Krammer, P. H.: Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood, 81: 2067, 1993.
26. Altomonte, M., Gloghini, A., Bertola, G., Gasparollo, A., Carbone, A., Ferrone, S. and Maio, M.: Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res., 53: 3343, 1993.
27. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C. and Tschopp, J.: Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science, 274: 1363, 1996.
28. Nagata, S.: Fas ligand and immune evasion. Nature Med., 2: 1306, 1996.
29. Owen-Schaub, L. B., Angelo, L. S., Radinsky, R., Ware, C. F., Gesner, T. G. and Bartos, D. P.: Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis ? Cancer Lett., 94: 1, 1995.
30. Weller, M., Malipiero, U., Rensing-Ehl, A., Barr, P. J. and Fontana, A.: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res., 55: 2936, 1995.